hotspot -WSS

hotspot

author：focus 2025-10-02 19:39:19 - browse：44

Photo illustration of Fyodor Urnov surrounded by DNA strands. -- health coverage from STAT — Christine Kao/STAT

Researchers attending gene therapy meetings over the past couple years were liable to bump into a svelte, graying scientist explaining in emphatic, Russian-inflected English that the U.S. was wasting the grand potential of CRISPR gene editing.

Fyodor Urnov, the scientist in question, estimates he gave the talk 30 to 40 times: to fellow researchers, pharma executives, Food and Drug Administration officials, congressional staff, journalists, patient advocates. “Anyone who would listen,” he says.

The problem was one of scale. Sure, for-profit companies were developing cures for a small handful of genetic diseases, such as sickle cell disease. But there were hundreds of devastating conditions that CRISPR might be able to cure but that no entity was seriously working on.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

WSS

Biden jokes that Republicans may impeach him because inflation is starting to cool down

Dewpoint Therapeutics lays off staff after losing partnerships

The surgeon had a dilemma only a Nazi medical text could resolve

How digital therapeutics firms are pivoting after Pear's bankruptcy

Biden to sign 'historic' executive order on how US military handles sexual assault cases

The mammogram wars are not over

explore

hotspot

knowledge

Alkermes shareholders re

Biden announces an advanced cancer research initiative

Hepatitis C has a cure — but many Americans still lack access to it

Why doctors need education on FDA device approval process

Affirmative action in medical school literally saved lives

Francis Collins on trust in science and how Covid communications failed

New air purifier tech could be key to improving indoor air quality

Will biotech layoffs continue through 2023?

Psychedelics group wrestles with new pharma identity

VC firm RA Capital starts a new synthetic biology incubator

hotspot

New brain studies show LSD's effects on the brain in full color

Biden announces an advanced cancer research initiative

Readout Newsletter: Merck, J&J, and long Covid

CDC: Cases of alpha

Prior authorization will have to move faster under new Biden rule

AI generated plenty of interest at JPM but not a lot of trust

entertainment

explore

focus

focus